Earnings Highlights
EPS Actual
-0.38
EPS Estimate
-0.32
Revenue Actual
Revenue Estimate
***
contextual analysis Our platform delivers equity research covering earnings momentum, market sentiment, and technical trading signals. Roivant Sciences reported a first-quarter 2026 loss per share of -$0.38, falling short of the consensus estimate of -$0.324 by 17.28%. The company reported no revenue during the quarter, consistent with its pre-commercial biotech stage. Following the announcement, shares declined by approximately 0.97%, reflecting investor disappointment with the wider-than-expected net loss.